These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12400997)

  • 1. Antisense therapy: current status in prostate cancer and other malignancies.
    Gleave M; Miyake H; Zangemeister-Wittke U; Jansen B
    Cancer Metastasis Rev; 2002; 21(1):79-92. PubMed ID: 12400997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer.
    Gleave M; Nelson C; Chi K
    Curr Drug Targets; 2003 Apr; 4(3):209-21. PubMed ID: 12643471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clusterin and IGFBPs as antisense targets in prostate cancer.
    Gleave M; Jansen B
    Ann N Y Acad Sci; 2003 Dec; 1002():95-104. PubMed ID: 14751827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
    Gleave ME; Miyake H; Zellweger T; Chi K; July L; Nelson C; Rennie P
    Urology; 2001 Aug; 58(2 Suppl 1):39-49. PubMed ID: 11502446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.
    Gleave ME; Zellweger T; Chi K; Miyake H; Kiyama S; July L; Leung S
    Invest New Drugs; 2002 May; 20(2):145-58. PubMed ID: 12099575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.
    Gleave M; Miyake H
    World J Urol; 2005 Feb; 23(1):38-46. PubMed ID: 15770517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense approaches in prostate cancer.
    Chi KN; Gleave ME
    Expert Opin Biol Ther; 2004 Jun; 4(6):927-36. PubMed ID: 15174974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
    BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotide therapy in cancer.
    Stephens AC; Rivers RP
    Curr Opin Mol Ther; 2003 Apr; 5(2):118-22. PubMed ID: 12772500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin.
    Zellweger T; Chi K; Miyake H; Adomat H; Kiyama S; Skov K; Gleave ME
    Clin Cancer Res; 2002 Oct; 8(10):3276-84. PubMed ID: 12374699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense therapy for cancer--the time of truth.
    Jansen B; Zangemeister-Wittke U
    Lancet Oncol; 2002 Nov; 3(11):672-83. PubMed ID: 12424069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
    Zellweger T; Miyake H; July LV; Akbari M; Kiyama S; Gleave ME
    Neoplasia; 2001; 3(4):360-7. PubMed ID: 11571636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
    Zellweger T; Miyake H; Cooper S; Chi K; Conklin BS; Monia BP; Gleave ME
    J Pharmacol Exp Ther; 2001 Sep; 298(3):934-40. PubMed ID: 11504787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgens and prostate cancer.
    So AI; Hurtado-Coll A; Gleave ME
    World J Urol; 2003 Nov; 21(5):325-37. PubMed ID: 14586548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of antisense therapy: combination with anticancer treatments.
    Biroccio A; Leonetti C; Zupi G
    Oncogene; 2003 Sep; 22(42):6579-88. PubMed ID: 14528283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-generation antisense drug for prostate cancer.
    Kerr C
    Lancet Oncol; 2004 Nov; 5(11):646. PubMed ID: 15536686
    [No Abstract]   [Full Text] [Related]  

  • 17. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy.
    July LV; Akbari M; Zellweger T; Jones EC; Goldenberg SL; Gleave ME
    Prostate; 2002 Feb; 50(3):179-88. PubMed ID: 11813210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
    Miyake H; Nelson C; Rennie PS; Gleave ME
    Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression.
    Miyake H; Hara I; Kamidono S; Gleave ME; Eto H
    Oncol Rep; 2003; 10(2):469-73. PubMed ID: 12579291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Short-term neoadjuvant hormone therapy enhanced expression of clusterin in prostate cancer].
    Niu YN; Xin DQ; He ZS; Zhou LQ; Pan BN; Na YQ; Guo YL
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):394-7. PubMed ID: 15854351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.